Skip to main content

Kymera Therapeutics

Partnership since March 2020


In March 2020, LLS made an equity investment in Kymera Therapeutics to "Support Studies with Protein Degraders for Development in Hematological Patients."

Kymera received this strategic investment from LLS TAP to advance work in an emerging approach to cancer therapy, called “targeted protein degradation.” Whereas most targeted therapies inhibit or inactivate the proteins or genes that drive the cancer, targeted protein degradation harnesses the body’s natural system of ridding itself of unwanted, “old” or “broken” components of cells.

Kymera Therapeutics is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

KT-333 is STAT3 protein degrader and is enrolling NHL patients in a Phase 1 clinical trial (NCT05225584).

KT-253 is a MDM2 protein degrader and is enrolling AML patients in a Phase 1 clinical trial (NCT05775406).

For more information about Kymera, visit

Recent News

  • January 9, 2024 - announced closing of upsized $316.2M public offering and outlined key 2024 objectives and strategy
  • September 18, 2023 - announced that the FDA has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma (CTCL) and R/R Peripheral T-cell Lymphoma (PTCL).
  • June 9, 2023 - announced new data demonstrating KT-333 continue to demonstrate substantial target knockdown in ongoing a Phase 1a dose escalation clinical trial, with no dose limiting toxicities observed. The data were shared as part of the International Conference on Malignant Lymphoma (ICML), taking place from June 13-17, 2023, in Lugano, Switzerland.
  • December 12, 2022 - announced that preclinical data from collaboration for its STAT3 degrader was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 - 13, 2022 in New Orleans, Louisiana.
  • July 15, 2022 - recently dosed the first patient in Phase 1 clinical trial evaluating the STAT3 degrader KT-333. The KT-333 trial includes patients with relapsed/refractory liquid and solid tumors, including T cell lymphomas and leukemia.
  • June 1, 2022 - announced that the FDA has granted orphan drug designation to KT-333 for the treatment of Peripheral T-cell Lymphoma (PTCL). 
  • December 13, 2021 - announced the company presented new preclinical data for its STAT3 degraders, including its first-in-class KT-333 STAT3 degrader, at the virtual 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11 – 14, 2021 in Atlanta, GA and virtually.